Cancer is one of the leading causes of rate mortality worldwide.[1-3] Early treatment of the cancer can significantly reduce the mortality. Pancreatic Ductal Adenocarcenoma (PDAC) is one of these cancers where patient mortality is reduced by early detection and treatment. PDAC is one of the top 7 cancer-related diseases worldwide that contributes to this mortality rate and is projected to be the 3rd leading cause of cancer deaths by 2025. In most cases, PDAC remains asymptomatic during the early developmental stages making it extremely difficult to detect. Only a small percentage of patients end up discovering the early-stage disease, usually as a result of investigating other ailments[6-9], and receive invasive surgical procedures and treatments to increase their life expectancy. [5, 10] There is a significant unmet clinical need to detect cancer, especially pancreatic cancer, in the early stages where treatments are more effective.